Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
| العنوان: | Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the |
|---|---|
| المؤلفون: | Kevin V. Carlson, Kavita V. Nair, Eric S. Rovner, John Hairston, Rita M Kristy, Anna S. Deal |
| المصدر: | Lower Urinary Tract Symptoms |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Side effect, Urology, Registry study, 030232 urology & nephrology, Original Articles ‐ Clinical, Muscarinic Antagonists, Persistence (computer science), 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Internal medicine, medicine, Humans, Prospective Studies, Registries, antimuscarinics, 030219 obstetrics & reproductive medicine, Urinary Bladder, Overactive, business.industry, persistence, medicine.disease, Overactive bladder syndrome, mirabegron, Discontinuation, Thiazoles, Treatment Outcome, Neurology, Overactive bladder, PERSPECTIVE study, Urological Agents, Original Article, overactive bladder, Acetanilides, Mirabegron, business, medicine.drug |
| الوصف: | Objectives This analysis from the PERSPECTIVE (a Prospective, Non‐interventional Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder) study evaluated treatment persistence with mirabegron or antimuscarinics over a 12‐month period. Methods Participants were adults diagnosed with overactive bladder (OAB) by their health care provider (HCP), who were initiating mirabegron or antimuscarinic treatment. The HCP made all treatment decisions, and patients were followed for 12 months with no mandatory scheduled visits. Information requests were sent to patients at baseline and months 1, 3, 6, and 12. Patients were nonpersistent if they switched, discontinued, or added OAB medications/therapies to their initial treatment. Reasons for discontinuation and switching patterns were investigated. Results Overall, 1514 patients were included (613 mirabegron and 901 antimuscarinic initiators). Persistence rates decreased steadily over time in both groups. A low proportion of patients added or switched medication at each time point. Unadjusted Kaplan‐Meier analysis showed similar persistence rates for both groups. When the data were adjusted for patient characteristics (age, sex, and OAB treatment status), mirabegron initiators had higher persistence rates. No significant differences were noted in unadjusted median time to end of persistence. However, end of treatment persistence by any cause was longer with mirabegron (median: 9.5 vs 6.7 months for antimuscarinics). HCPs stated that the most common reasons for nonpersistence were no symptomatic improvement and side effect aversion. Conclusions Treatment persistence was longer for mirabegron compared with antimuscarinic initiators after controlling for patient characteristics. End of treatment persistence by any cause was also longer with mirabegron. |
| تدمد: | 1757-5672 1757-5664 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d81cb3dea2451535bfa51726e6a75f https://doi.org/10.1111/luts.12382 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....29d81cb3dea2451535bfa51726e6a75f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17575672 17575664 |
|---|